HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.

Abstract
The effect of combinations of the conventional chemotherapeutic agent 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and nitroimidazole radiation sensitizers was evaluated in female C3H mice. Tumour response to single-agent or combination therapy was assessed in a tumour growth-delay assay. In the KHT sarcoma the simultaneous addition of misonidazole (MISO) was found to increase significantly the tumour growth delay resulting from CCNU treatment. The observed enhancement ratios (ER) increased with MISO dose, and ranged from 1.3 to 1.9 for sensitizer doses of 0.25-1.0 mg/g. The combination of CCNU and 1.0 or 0.5 mg/g MISO in the RIF-1 tumour or the MT-1 tumour produced ERs of approximately 2.0 and approximately 1.5 respectively. In the KHT sarcoma a series of other nitroimidazole sensitizers, including Ro-05-9963, SR-2555, SR-2508 and metronidazole (METRO), were also evaluated at equimolar doses (5 mmol/kg) in combination with a 20mg/kg dose of CCNU. Unlike MISO, these compounds in general failed to enhance the CCNU cytotoxicity in this tumour model. However, SR-2508 did enhance the response of the RIF-1 tumour to large single doses of CCNU, though not as much as MISO. Normal-tissue toxicity was determined using peripheral white blood cell (WBC) counts 3 days after treatment. CCNU doses of 10-50 mg/kg given either alone or in simultaneous combination with 0.5 or 1.0 mg/g MISO were studied. WBC toxicity increased with CCNU dose, but the addition of MISO at either dose did not significantly enhance this normal-tissue toxicity.
AuthorsD W Siemann
JournalBritish journal of cancer (Br J Cancer) Vol. 45 Issue 2 Pg. 272-81 (Feb 1982) ISSN: 0007-0920 [Print] England
PMID6460517 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Nitroimidazoles
  • Nitrosourea Compounds
  • Radiation-Sensitizing Agents
  • Metronidazole
  • Etanidazole
  • SR 2555
  • Lomustine
  • Misonidazole
  • desmethylmisonidazole
Topics
  • Animals
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Etanidazole
  • Female
  • Leukocyte Count
  • Lomustine (therapeutic use)
  • Metronidazole (therapeutic use)
  • Mice
  • Mice, Inbred C3H
  • Misonidazole (analogs & derivatives, therapeutic use)
  • Nitroimidazoles (therapeutic use)
  • Nitrosourea Compounds (therapeutic use)
  • Radiation-Sensitizing Agents (therapeutic use)
  • Sarcoma, Experimental (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: